ClinicalTrials.gg

Program

QLH12016

A development code.

Its studies are mostly in Prostatic Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 2, since Jul 29, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical33 open or runningphase 2since Jul 29, 2025Jul 17, 2023Dec 2026phase 2 · NCT07198633

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2023First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT05973149 · 108 planned · China
  2. Jul 29, 2025Phase 2 study in Prostatic NeoplasmsNCT07104110 · 50 planned
  3. Sep 15, 2025Phase 2 study in Advanced Prostate CancerNCT07198633 · 212 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Prostate CancerNCT07198633
  2. Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07104110

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07198633Advanced Prostate Cancer · China2RecruitingDec 2026212
NCT07104110Prostatic Neoplasms2Not yet recruitingOct 202750
NCT05973149Prostatic Neoplasms · China1Not yet recruitingAug 31, 2025108

How it is read

Names in the registry

  • “QLH12016”, 3 entries

Codes read as this program: QLH12016.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.